Winslow Garrett sold $7K of DMRA
Winslow Garrett (General Counsel) sold 245 shares of Damora Therapeutics, Inc. (DMRA) at $29.98 on 2026-07-06.
How this was made
The 30-second read
Why it matters
This provides a fresh datapoint on officer selling (245 shares) but does not disclose any new operational, financial, or regulatory development for DMRA.
Market read
Traders may note the insider sale, but the disclosed value (~$7.3k) and lack of company-specific catalysts make it unlikely to drive meaningful repricing.
What to watch
Insider sales can be driven by taxes, diversification, or pre-existing compensation schedules; without additional context or larger/clustered trades, the signal is weak.
Background
The article is a SEC Form 4 insider transaction disclosure for Damora Therapeutics, Inc. (DMRA).
Ticker impact
Damora Therapeutics’ general counsel Winslow Garrett sold 245 shares at $29.98/share for $7,345.10 via an open-market sale.
Minimal, unless follow-on insider selling accelerates or broader news emerges.
The filing is a small, routine Form 4 transaction by an officer; it does not include new company performance, guidance, or regulatory/clinical catalysts.
Market effects
None—this is company-specific insider transaction data without sector-wide implications.
None.
None.
Counterpoint
The absence of a disclosed 10b5-1 plan could be read as discretionary selling, but the transaction size is small and may reflect personal liquidity rather than a thesis.
Key entities
- issuerDamora Therapeutics, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderWinslow Garrett
General Counsel who executed the open-market sale.